Arrivo Bio today announced that members of its executive management team will participate in the 37th Annual Piper Sandler Healthcare Conference, being held on December 2–4 in New York, New York. The team will host investor meetings and present an overview of the Company’s business and pipeline.

Presentation Details:

• Date: Thursday, December 4, 2025
• Time: 1:30-1:50pm ET
• Participants: Steve Butts, Co-founder and Chief Executive Officer, and Greg Rigdon PhD, Senior Vice President of Scientific Affairs

About Arrivo Bio

Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251119699158/en/